Molnupiravir (MK-4482/EIDD-2801) acts as against SARS-CoV-2
This potential antiviral agent is capable of combating infection from SARS-CoV-2, and is the outcome of a collaborative effort of both Ridgeback Biotherapeutics and Merck. It was established that Molnupiravir is capable of suppressing completely, the transmission of the virus within 24 hours.
Molnupiravir is said to possess broad spectrum activity against respiratory RNA viruses that treatment with this drug significantly reduced the amount of viral load shed by several orders of magnitude, thus significantly lowering transmission. This led the team to suggest the use of this agent in the prevention of transmission of the virus.
Although a ferret model was adopted to determine the spread of the virus, this was because the animals were determined as good transmitters of the virus. Observation was that the infected ferrets did not transmit the virus infected and non-infected ferrets were housed together.
Molnupiravir is a demonstration of an oral agent capable of preventing transmission of the virus and is the first of its kind.